TY - JOUR AU - Ridwan, Antonius Janes AU - Suryanti, Sri AU - Hassan, Abdul Hadi AU - Hernowo, Bethy S PY - 2015/08/31 Y2 - 2024/03/29 TI - ANALYSIS OF IMMUNOEXPRESSION OF ESTROGEN RECEPTOR BETA AND EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) ON TESTICULAR SEMINOMAS NONRECURRENCE AND RECURRENCE JF - Journal of Medicine and Health JA - J. Med. Health VL - 1 IS - 2 SE - Articles DO - 10.28932/jmh.v1i2.507 UR - https://journal.maranatha.edu/index.php/jmh/article/view/507 SP - AB - <p><em>T</em><em>he most common malignancy of testis</em><em> is seminoma with</em><em> prognosis </em><em>that is</em><em> not always good because of high recurrence rate and death cases. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a glycoprotein adhesion molecules</em><em> which</em><em> plays</em><em> a</em><em> role in tumor cell invasion and metastasis as evidenced by immunohistochemistry method in several types of tumor cells and tissue </em><em>that </em><em>shows </em><em>the </em><em>correlation to the clinical progessivity.This study was conducted by observational descriptive analytic</em><em>s</em><em> with </em><em>each seven </em><em>cases</em><em> of</em><em> seminoma nonrecurrences and recurrences diagnosed histopathologically from Dr.Hasan Sadikin Hospital, Advent Hospital and St.Borromeus Hospital </em><em>in </em><em>Bandung.</em><em> </em><em>This study </em><em>shows</em><em> that immunoexpression of estrogen receptor beta </em><em>is </em><em>not higher in testicular seminoma recurrence compared with nonreccurence</em><em>.</em><em> </em><em>T</em><em>here was no higher imunoexpression of EMMPRIN receptor on testicular seminoma recurrence compared with nonrecurrence;</em><em> besides,</em><em> there was no relationship between immunoexspression of estrogen receptor beta and EMMPRIN in testicular seminoma nonrecurrence and recurrence.In conclusion, immunoexpression estrogen receptor beta expressed in all testicular seminoma, so that the patient could be given an alternative therapy and immunoexspression EMMPRIN</em><em>,</em><em> </em><em>cannot</em><em> be used to predict </em><em>a </em><em>recurrence in patients with seminoma who </em><em>has</em><em> received complete therapy.</em></p><p><em>                                                        </em></p><p><strong><em>Keywords:</em></strong><em> EMMPRIN, Estrogen Receptor Beta, Seminoma Testis nonrecurrence and recurrence</em></p> ER -